A common immunological epitope existing between HIV-1 gp41 and human interferon-α and -β

被引:10
|
作者
Chen, YH
Dierich, MP
机构
[1] Univ Innsbruck, Inst Hyg, A-6010 Innsbruck, Austria
[2] Tsinghua Univ, Immunol Lab, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China
关键词
D O I
10.1016/S0171-2985(98)80043-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Based on the similar effects that HIV-1 gp41 like human type I interferons (IFN-alpha and -beta) upregulated MHC expression and inhibited lymphocyte proliferation, we compared amino acid sequences of gp41 and human type I interferons (IFN-alpha and -beta), and found sequence-similarity existing between the immunosuppressive domain (aa583-599, LQARILAV-ERYLKDQQL) of HIV-1 gp41 and human IFN-alpha (region aa117-129) and IFN-beta (region aa128-134); besides, the immunosuppressive domain of HIV-1 gp41 shows sequence-homology with bovine and murine IFN-alpha and IFN-beta in the same region. We examined polyclonal antibodies to human IFN-alpha and IFN-beta respectively and found that both antibodies could recognize rsgp41 from two different sources. The polyclonal antibody to IFN-beta could bind to the immunosuppressive peptide (ISP, aa583-599, LQARILAVERYLKDQQL) of HIV-1 gp41, only when the ISP was coupled with carrier-protein, and inhibit, if preincubated with rsgp41, binding of rsgp41 to human H9 (T cells), Rail (B cells), and U937 (monocyte cells) completely. The polyclonal antibody to IFN-alpha could partially inhibit the binding of rsgp41 to U937 and Raji. These results indicate that a common immunological epitope exists between HIV-1 gp41 and human type I interferons.
引用
收藏
页码:333 / 342
页数:10
相关论文
共 50 条
  • [21] Comparative immunological properties of lipidated HIV-1 gp41 fragments on various structural templates
    Pedyczak, A
    McLeod, D
    James, O
    Klein, M
    Chong, P
    PEPTIDES: FRONTIERS OF PEPTIDES SCIENCE, 1999, : 777 - 778
  • [22] COMMON IMMUNOLOGICAL DETERMINANT BETWEEN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP41 AND ASTROCYTES
    YAMADA, M
    ZURBRIGGEN, A
    OLDSTONE, MBA
    FUJINAMI, RS
    JOURNAL OF VIROLOGY, 1991, 65 (03) : 1370 - 1376
  • [23] HIV-1 gp41 Fusion Intermediate: A Target for HIV Therapeutics
    Pan, Chungen
    Liu, Shuwen
    Jiang, Shibo
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2010, 109 (02) : 94 - 105
  • [24] Biological function of HIV-1 transmembrane protein gp41 - A study on a putative cellular receptor of gp41
    Chen, YH
    Dierich, MP
    CHINESE SCIENCE BULLETIN, 1998, 43 (19): : 1630 - 1635
  • [26] Trilobatin as an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope
    Yin, Shuwen
    Zhang, Xuanxuan
    Lai, Fangyuan
    Liang, Taizhen
    Wen, Jiayong
    Lin, Wanying
    Qiu, Jiayin
    Liu, Shuwen
    Li, Lin
    FEBS LETTERS, 2018, 592 (13) : 2361 - 2377
  • [27] Structure of the epitope-fragment 579 to 601-in the GP41 transmembrane domain of HIV-1
    Desai, P
    Coutinho, E
    Srivastava, S
    Saran, A
    INDIAN JOURNAL OF CHEMISTRY SECTION A-INORGANIC BIO-INORGANIC PHYSICAL THEORETICAL & ANALYTICAL CHEMISTRY, 2000, 39 (1-3): : 274 - 280
  • [28] Diversity of the immunodominant epitope of gp41 of HIV-1 subtype O and its validity for antibody detection
    Eberle, J
    LoussertAjaka, I
    Brust, S
    Zekeng, L
    Hauser, PH
    Kaptue, L
    Knapp, S
    Damond, F
    Saragosti, S
    Simon, F
    Gurtler, LG
    JOURNAL OF VIROLOGICAL METHODS, 1997, 67 (01) : 85 - 91
  • [29] Structure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing Epitope
    Stanfield, Robyn L.
    Julien, Jean-Philippe
    Pejchal, Robert
    Gach, Johannes S.
    Zwick, Michael B.
    Wilson, Ian A.
    JOURNAL OF MOLECULAR BIOLOGY, 2011, 414 (03) : 460 - 476
  • [30] Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein
    Coëffier, E
    Clément, JM
    Cussac, V
    Khodaei-Boorane, N
    Jehanno, M
    Rojas, M
    Dridi, A
    Latour, M
    El Habib, R
    Barré-Sinoussi, F
    Hofnung, M
    Leclerc, C
    VACCINE, 2000, 19 (7-8) : 684 - 693